Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates – Yahoo Finance

DeFi expert Jim Bianco joins Jared Blikre to break down an interesting year ahead on Wednesday, 1/12 at 2PM ET.

– Achieved Full Year 2021 Preliminary Global Net Product Revenues of $662 Million, Representing 83% Annual Growth Compared to 2020 –
– Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.4 Billion –
CAMBRIDGE, Mass., January 09, 2022–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2021 global net product revenues for ONPATTRO, GIVLAARI and OXLUMO and provided additional updates on the products’ commercial launches.
2021 Preliminary Commercial and Financial Performance*
ONPATTRO® (patisiran), a commercial-stage RNAi therapeutic targeting transthyretin (TTR) for the treatment of polyneuropathy in adult patients with hATTR amyloidosis.
Preliminary global net product revenues for the fourth quarter and full year 2021 were approximately $139 million and $475 million, respectively, representing quarterly and annual growth of 15% and 55% compared to Q3 2021 and full year 2020, respectively.
As of year-end 2021, over 2,050 patients worldwide were receiving commercial ONPATTRO.
GIVLAARI® (givosiran), a commercial-stage RNAi therapeutic for the treatment of adults with acute hepatic porphyria (AHP).
Preliminary global net product revenues for the fourth quarter and full year 2021 were approximately $41 million and $128 million, respectively, representing quarterly and annual growth of 28% and 132% compared to Q3 2021 and full year 2020, respectively.
As of year-end 2021, over 350 patients worldwide were receiving commercial GIVLAARI.
OXLUMO® (lumasiran), a commercial-stage RNAi therapeutic for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients.
Preliminary global net product revenues for the fourth quarter and full year 2021 were approximately $19 million and $60 million, respectively, representing quarterly growth of 29% compared to Q3 2021.
As of year-end 2021, over 140 patients worldwide were receiving commercial OXLUMO.
Finally, the Company today reported that it expects its full year 2021 non-GAAP operating loss to be substantially improved relative to the prior year, as the Company continues to transition toward a self-sustainable financial profile.
Further, at December 31, 2021, Alnylam had preliminary cash, cash equivalents, and marketable securities of approximately $2.4 billion, as compared to $1.9 billion at December 31, 2020.
"We are pleased to have closed out 2021 on a very strong note with continued execution across our commercial portfolio, delivering top-line revenue at the upper end of our guidance range. These preliminary results reflect the dedication of our teams to deliver these important medicines to patients in need around the world, despite the variable dynamics posed by the ongoing pandemic. We’re also excited to have ended the year with Leqvio, partnered with Novartis, becoming the fourth RNAi therapeutic approved in the U.S., and the first indicated to treat a major risk factor for a highly prevalent disease," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "Furthermore, as we reflect upon the one year anniversary of the announcement of our Alnylam P5x25 strategy, we believe we are well on our way to achieving or potentially exceeding these ambitious goals, positioning Alnylam as a top-tier, global, multi-product commercial company with a broad pipeline and organic platform poised to deliver sustainable innovation well into the future, a profile rarely seen in our industry."
Alnylam management will discuss these preliminary selected financial results and commercial updates during a webcast presentation at the 40th Annual J.P. Morgan Healthcare Conference, being held virtually, tomorrow, Monday, January 10, 2022 at 9:45 am ET.
About RNAi Therapeutics
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam's expectations, plans, aspirations, and goals, including, without limitation, those related to its unaudited, preliminary selected financial results for 2021, and its aspiration to become a leading biotech company, and the planned achievement or potential exceeding of its "Alnylam P5x25" strategy, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam’s efforts to mitigate the impact of the pandemic; the potential impact of the recent leadership transition on Alnylam’s ability to attract and retain talent and to successfully execute on its "Alnylam P5x25" strategy; the finalization and audit of its fourth quarter and 2021 fiscal year financial results which could potentially result in changes or adjustments to the selected preliminary financial results presented herein; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication for ONPATTRO (and potentially vutrisiran, if approved) in the future; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products, including Novartis, Regeneron and Vir; the outcome of litigation; the potential impact of a current government investigation and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the "Risk Factors" filed with Alnylam's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
* The preliminary selected financial results are unaudited, subject to adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results in February 2022.
View source version on
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
Josh Brodsky
Scared of sky-high stock prices? These dirt-cheap stocks are good bets for 2022.
The billionaire investor expects the U.S. dollar to "slip pretty mightily."
From Elon Musk to Jack Dorsey, and Ark Investment's Cathie Wood, here's how world's top crypto believers gathered more bitcoin when it was falling.
While many companies are scrambling to carve out their part of the metaverse, Nvidia is already marketing a successful product. Nvidia's graphics processing units (GPUs) should enjoy tremendous demand over the long term as well as the metaverse is built. Few companies can compete at the same level as Nvidia in powering virtual reality apps.
It's been eight months since I sold my stake in AT&T. When the stock moved higher on the news — even after the company announced it would lower its quarterly payouts — that was all I needed to get out.
Death cross’ past record as an indicator of deeper drawdowns is mixed.
These solid companies are getting unfairly punished by the market. Savvy investors should take note.
The 2022 market has been an expectation breaker so far, with the Nasdaq and Tesla selling off hard. Here's what to do now.
Buying a stock is easy, but buying the right stock without a time-tested strategy is incredibly hard. So what are the best stocks to buy now or put on a watchlist?
In this article, we discuss the 10 best AI stocks for 2022. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best AI Stocks for 2022. Artificial intelligence is the backbone of a myriad of innovations in today’s world such as self-driving cars, high-tech computing, enterprise solutions, and robotics […]
Thanks to the dual headwinds of sky-high inflation and the threat of rising interest rates, biopharmaceutical stocks appear poised for a turbulent 2022. Underscoring this point, investors have been dumping risky clinical and early commercial-stage biopharma stocks over the past several weeks in response to these closely intertwined macro variables. This year thus seems destined to be a bona fide "stock-picker's market" for biopharma investors.
One industry that is becoming increasingly important to our economy and will surely continue to breed some long-term investment winners is the semiconductor industry. The chip market is forecast to see sales rise by 8.8% to reach $601 billion in 2022, according to the Semiconductor Industry Association. The ongoing buildout of data centers and other high-performance applications is a big tailwind for leading component suppliers.
Inflation data will be in focus this week, with investors set to receive the Bureau of Labor Statistics' (BLS) latest Consumer Price Index (CPI) as the Federal Reserve's next monetary policy moves remain in focus. Quarterly earnings season also ramps up as some of the big banks report results.
(Bloomberg) — Sign up for the New Economy Daily newsletter, follow us @economics and subscribe to our podcast.Most Read from BloombergCypriot Scientist Says Deltacron Covid Variant Isn’t ErrorCyprus Finds Covid-19 Infections That Combine Delta and OmicronWorld’s Biggest Crypto Fortune Began With a Friendly Poker GameAlexandria Ocasio-Cortez Tests Positive for Covid-19Omicron Study in South Africa Points to End of Acute Pandemic PhaseThe Federal Reserve will likely raise interest rates four time
Piedmont Lithium stock ended 2021 off its highs but with a gain of 98%. Two insiders bought up shares as the year was coming to a close.
(Bloomberg) — To cryptocurrency true believers, Bitcoin is the ultimate store of value, the most solid hedge against the rampant inflation manufactured by reckless central banks and their money-printing. To skeptics, the crypto world as a whole is a mirage whose massive run-up past $2 trillion was simply the speculative byproduct of the extraordinary amount of easy cash that’s been sloshing around in the global economy — in effect, a big bubble.Most Read from BloombergCypriot Scientist Says Del
Whether at home, work, or play, software is likely to play a vital role in our activities. Due to annual recurring revenues (ARR), profitability, and high product demand, software companies make terrific investments. It is tough to talk about software stocks without mentioning the world's largest software company, Microsoft (NASDAQ: MSFT).
This fast-growing player and well-rounded value stock deserve pole-position in a long-term EV portfolio.
The market can seem like a popularity contest, and small and mid-cap growth stocks are not cool right now. Buy now, pay later (BNPL) took 2021 by storm, growing roughly fourfold to $100 billion this past year.
(Bloomberg) — Stocks in Asia nudged higher Monday as investors brace for bond-market volatility and stimulus withdrawal. The dollar rose.Most Read from BloombergCypriot Scientist Says Deltacron Covid Variant Isn’t ErrorCyprus Finds Covid-19 Infections That Combine Delta and OmicronWorld’s Biggest Crypto Fortune Began With a Friendly Poker GameAlexandria Ocasio-Cortez Tests Positive for Covid-19Omicron Study in South Africa Points to End of Acute Pandemic PhaseShares in Hong Kong advanced as tec

Connect with Chris Hood, a digital strategist that can help you with AI.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2022 AI Caosuo - Proudly powered by theme Octo